ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

Basit Öğe Kaydı
dc.contributor.authorCicin, Irfan
dc.contributor.authorMartin, Claudio
dc.contributor.authorHaddad, Carolina Kawamura
dc.contributor.authorKim, Sang -We
dc.contributor.authorSmolin, Alexey
dc.contributor.authorAbdillah, Arif
dc.contributor.authorYang, Xue
dc.date.accessioned2024-06-12T10:51:37Z
dc.date.available2024-06-12T10:51:37Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThis article reviews the role of ALK tyrosine kinase inhibitors (TKIs) in the literature and provides expert commentary on local use in Argentina, Brazil, China, Russia, South Korea, and Turkey. We identified 56 articles involving patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases (BM) treated with ALK TKIs published between January 2000 and June 2021. In first-line settings, central nervous system response rates in clinical trials with alectinib (86-94%), brigatinib (67-78%), and lorlatinib (42-82%) were generally higher than those reported with crizotinib (16-71%). Median progression-free survival in patients receiving crizotinib (5.6-7.4 months) was lower than alectinib (not reached), brigatinib (24.0 months), and ceritinib (10.7-25.2 months). Across these counties, next-generation TKIs are preferred for patients with progressing BM lesions. Although next-generation ALK TKIs demonstrate significant activity in these patients and following progression on crizotinib, access remains a challenge for personalized therapy.en_US
dc.identifier.doi10.1016/j.critrevonc.2022.103847
dc.identifier.issn1040-8428
dc.identifier.issn1879-0461
dc.identifier.pmid36257531en_US
dc.identifier.scopus2-s2.0-85141523749en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.critrevonc.2022.103847
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18422
dc.identifier.volume180en_US
dc.identifier.wosWOS:000921273700012en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofCritical Reviews In Oncology Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnaplastic Lymphoma Kinaseen_US
dc.subjectNon -Small Cell Lung Canceren_US
dc.subjectBrain Metastasesen_US
dc.subjectALK Tkisen_US
dc.subjectNervous-System Progressionen_US
dc.subjectTyrosine Kinase Inhibitorsen_US
dc.subjectOpen-Labelen_US
dc.subjectSingle-Armen_US
dc.subjectMotexafin Gadoliniumen_US
dc.subjectCrizotinib Ascend-5en_US
dc.subjectClinical Impacten_US
dc.subjectJ-Alexen_US
dc.subjectAlectiniben_US
dc.subjectCeritiniben_US
dc.titleALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiencesen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu